CL2023000639A1 - Tratamientos de angioedema hereditario - Google Patents

Tratamientos de angioedema hereditario

Info

Publication number
CL2023000639A1
CL2023000639A1 CL2023000639A CL2023000639A CL2023000639A1 CL 2023000639 A1 CL2023000639 A1 CL 2023000639A1 CL 2023000639 A CL2023000639 A CL 2023000639A CL 2023000639 A CL2023000639 A CL 2023000639A CL 2023000639 A1 CL2023000639 A1 CL 2023000639A1
Authority
CL
Chile
Prior art keywords
treatments
hereditary angioedema
hae
demand
present
Prior art date
Application number
CL2023000639A
Other languages
English (en)
Inventor
Paul Feener Edward
Louise Marsh Sally
MAETZEL Andreas
David Smith Michael
Martyn Yea Christopher
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of CL2023000639A1 publication Critical patent/CL2023000639A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invención se refiere a tratamientos de angioedema hereditario (HAE). En particular, la presente invención proporciona tratamientos a solicitud de angioedema hereditario (HAE) mediante la administración oral de un inhibidor de calicreína del plasma a un paciente que lo necesita a solicitud. Se proporciona también tratamientos regulares (o continuos) de HAE.
CL2023000639A 2019-06-14 2023-03-06 Tratamientos de angioedema hereditario CL2023000639A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861725P 2019-06-14 2019-06-14
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema

Publications (1)

Publication Number Publication Date
CL2023000639A1 true CL2023000639A1 (es) 2023-10-30

Family

ID=67700145

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021003244A CL2021003244A1 (es) 2019-06-14 2021-12-06 Tratamientos de angioedema hereditario
CL2023000639A CL2023000639A1 (es) 2019-06-14 2023-03-06 Tratamientos de angioedema hereditario

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2021003244A CL2021003244A1 (es) 2019-06-14 2021-12-06 Tratamientos de angioedema hereditario

Country Status (30)

Country Link
US (1) US20220218680A1 (es)
EP (2) EP4282474A3 (es)
JP (2) JP7356518B2 (es)
KR (1) KR20220024220A (es)
CN (1) CN114126612A (es)
AR (1) AR119158A1 (es)
AU (1) AU2020293614A1 (es)
BR (1) BR112021024664A2 (es)
CA (1) CA3142218A1 (es)
CL (2) CL2021003244A1 (es)
DK (1) DK3982960T3 (es)
EA (1) EA202193019A1 (es)
ES (1) ES2956471T3 (es)
FI (1) FI3982960T3 (es)
GB (1) GB201910116D0 (es)
HR (1) HRP20230696T1 (es)
HU (1) HUE063163T2 (es)
IL (1) IL288615A (es)
LT (1) LT3982960T (es)
MA (1) MA56187B1 (es)
MD (1) MD3982960T2 (es)
MX (1) MX2021014557A (es)
PL (1) PL3982960T3 (es)
PT (1) PT3982960T (es)
RS (1) RS64412B1 (es)
SG (1) SG11202113304YA (es)
SI (1) SI3982960T1 (es)
TW (1) TW202112370A (es)
WO (1) WO2020249977A1 (es)
ZA (1) ZA202110685B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20230381162A1 (en) * 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
US20240122909A1 (en) 2021-02-09 2024-04-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
WO2012004678A2 (en) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor

Also Published As

Publication number Publication date
JP2023166406A (ja) 2023-11-21
CA3142218A1 (en) 2020-12-17
EP3982960B1 (en) 2023-06-28
EP4282474A2 (en) 2023-11-29
BR112021024664A2 (pt) 2022-05-31
EP3982960A1 (en) 2022-04-20
RS64412B1 (sr) 2023-09-29
TW202112370A (zh) 2021-04-01
AR119158A1 (es) 2021-12-01
CL2021003244A1 (es) 2022-09-30
EP4282474A3 (en) 2024-02-14
KR20220024220A (ko) 2022-03-03
JP7356518B2 (ja) 2023-10-04
SI3982960T1 (sl) 2023-10-30
SG11202113304YA (en) 2021-12-30
JP2022536287A (ja) 2022-08-15
EA202193019A1 (ru) 2022-03-24
MA56187B1 (fr) 2023-09-27
GB201910116D0 (en) 2019-08-28
IL288615A (en) 2022-02-01
DK3982960T3 (da) 2023-08-21
PL3982960T3 (pl) 2024-01-15
HRP20230696T1 (hr) 2023-10-13
ES2956471T3 (es) 2023-12-21
LT3982960T (lt) 2023-08-25
MD3982960T2 (ro) 2023-12-31
ZA202110685B (en) 2024-06-26
MX2021014557A (es) 2022-01-11
AU2020293614A1 (en) 2022-01-27
CN114126612A (zh) 2022-03-01
WO2020249977A1 (en) 2020-12-17
US20220218680A1 (en) 2022-07-14
HUE063163T2 (hu) 2023-12-28
MA56187A (fr) 2022-04-20
PT3982960T (pt) 2023-09-26
FI3982960T3 (fi) 2023-08-29

Similar Documents

Publication Publication Date Title
CL2023000639A1 (es) Tratamientos de angioedema hereditario
CL2023000699A1 (es) Tratamientos de angioedema
MX2022000711A (es) Inhibidores de parp1.
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
NI200900106A (es) Inhibidores de la actividad de la akt.
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
BR112018011622A2 (pt) método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
PH12018500678A1 (en) Human plasma kallikrein inhibitors
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
BR112018000589A2 (pt) composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição
MX2020001254A (es) Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
MD3638370T2 (ro) Tratamentul migrenei cu acetil-leucină
PA8655401A1 (es) Nueva composicion farmaceutica que contiene por lo menos un derivado de dolastatina-10
CO2017012986A2 (es) Composición de péptidos multiples que comprende fragmentos ia-2 y pi
MX2016011002A (es) Tratamiento de angioedema hereditario con inhibidor c1.
MX2021009663A (es) Tratamiento del sindrome de pitt-hopkins.
MX2021008887A (es) Minociclina para el tratamiento del sindrome de pitt-hopkins.
AR128636A1 (es) Inhibidor de recaptación triple para el tratamiento de la depresión atípica
MX2016013281A (es) Proteina del factor fviia con vida media extendida para la prevencion y tratamiento de sangrado y regimenes de dosificacion de la misma.
BR112022013566A2 (pt) Compostos para distúrbios crônicos
RO130546A3 (ro) Unguent pentru tratamentul bolii hemoroidale